AF
Avanza Fonder Portfolio holdings
AUM
$3.38B
This Quarter Return
-4.89%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$3.05B
AUM Growth
-$320M
(-9.5%)
Cap. Flow
-$132M
Cap. Flow
% of AUM
-4.33%
Top 10 Holdings %
Top 10 Hldgs %
40.33%
Holding
468
New
31
Increased
49
Reduced
321
Closed
8
Top Buys
| 1 |
Linde
LIN
|
$21.1M |
| 2 |
Accenture
ACN
|
$13.2M |
| 3 |
Medtronic
MDT
|
$10.9M |
| 4 |
Chubb
CB
|
$7.73M |
| 5 |
Trane Technologies
TT
|
$6.84M |
Top Sells
| 1 |
Microsoft
MSFT
|
$20.1M |
| 2 |
NVIDIA
NVDA
|
$16.8M |
| 3 |
Amazon
AMZN
|
$13.1M |
| 4 |
Apple
AAPL
|
$10.9M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$6.97M |
Sector Composition
| 1 | Technology | 34.06% |
| 2 | Consumer Discretionary | 14.72% |
| 3 | Financials | 13.56% |
| 4 | Healthcare | 12.28% |
| 5 | Communication Services | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
WillScot Mobile Mini Holdings
WSC
$4.32B
| $119K | ﹤0.01% |
4,088
-2,596
| -39% | -$75.3K |
|
427
Merus
MRUS
$5.1B
| $118K | ﹤0.01% |
+2,749
| New | +$118K |
|
428
Energy Recovery
ERII
$767M
| $116K | ﹤0.01% |
7,274
| – | – |
|
429
Health Catalyst
HCAT
$238M
| $116K | ﹤0.01% |
26,050
| – | – |
|
430
Summit Therapeutics
SMMT
$19.3B
| $113K | ﹤0.01% |
5,535
-910
| -14% | -$18.6K |
|
431
NewAmsterdam Pharma
NAMS
$3.04B
| $113K | ﹤0.01% |
+6,205
| New | +$113K |
|
432
Arcellx
ACLX
$4.03B
| $110K | ﹤0.01% |
1,643
-755
| -31% | -$50.8K |
|
433
Alarm.com
ALRM
$2.84B
| $110K | ﹤0.01% |
1,975
| – | – |
|
434
Lennar Class B
LEN.B
$35.3B
| $109K | ﹤0.01% |
994
-52
| -5% | -$5.7K |
|
435
Kadant
KAI
$3.85B
| $104K | ﹤0.01% |
296
-168
| -36% | -$58.8K |
|
436
Pacific Biosciences
PACB
$381M
| $103K | ﹤0.01% |
80,727
+4,319
| +6% | +$5.49K |
|
437
Revolution Medicines
RVMD
$7.57B
| $99.5K | ﹤0.01% |
2,877
-1,073
| -27% | -$37.1K |
|
|
VRNA
438
Verona Pharma
VRNA
$9.2B
| $99.5K | ﹤0.01% |
+1,651
| New | +$99.5K |
|
439
Graphic Packaging
GPK
$6.38B
| $96.4K | ﹤0.01% |
3,665
-3,341
| -48% | -$87.9K |
|
440
Harmony Biosciences
HRMY
$2.07B
| $95.1K | ﹤0.01% |
2,924
-1,276
| -30% | -$41.5K |
|
441
Laureate Education
LAUR
$4.1B
| $93K | ﹤0.01% |
+4,457
| New | +$93K |
|
|
BCAX
442
Bicara Therapeutics Inc. Common Stock
BCAX
$658M
| $88.2K | ﹤0.01% |
+6,653
| New | +$88.2K |
|
443
Janux Therapeutics
JANX
$1.44B
| $86.1K | ﹤0.01% |
3,049
+444
| +17% | +$12.5K |
|
444
Bright Horizons
BFAM
$6.64B
| $83.8K | ﹤0.01% |
652
-184
| -22% | -$23.7K |
|
445
Cummins
CMI
$55.1B
| $76.8K | ﹤0.01% |
240
| – | – |
|
446
Bioceres Crop Solutions
BIOX
$163M
| $72.1K | ﹤0.01% |
+16,065
| New | +$72.1K |
|
447
Arq
ARQ
$302M
| $69.8K | ﹤0.01% |
16,615
+7,615
| +85% | +$32K |
|
|
MREO
448
Mereo BioPharma
MREO
$282M
| $66.6K | ﹤0.01% |
28,121
+8,521
| +43% | +$20.2K |
|
449
GXO Logistics
GXO
$6.02B
| $66.5K | ﹤0.01% |
1,658
-1,029
| -38% | -$41.3K |
|
450
Montrose Environmental
MEG
$1.07B
| $63.9K | ﹤0.01% |
4,700
-960
| -17% | -$13.1K |
|